Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age—A Bicenter Retrospective Study
Dominika Śmiałek, Sergiusz Jóźwiak, Katarzyna Kotulska
Journal of Clinical Medicine (2023) Vol. 12, Iss. 1, pp. 365-365
Open Access | Times Cited: 11

Showing 11 citing articles:

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT), a two-arm, randomized, observer-blind, controlled phase IIb national multicentre clinical trial: study protocol
Jan H. Driedger, Julian Schröter, Christoph Hertzberg, et al.
Orphanet Journal of Rare Diseases (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 3
An overview of the value of mTOR inhibitors to the treatment of epilepsy: the evidence to date
Patrick B. Moloney, Norman Delanty
Expert Review of Neurotherapeutics (2025)
Closed Access | Times Cited: 1
Evolving treatment strategies for early-life seizures in Tuberous Sclerosis Complex: A review and treatment algorithm
Debopam Samanta
Epilepsy & Behavior (2024) Vol. 161, pp. 110123-110123
Closed Access | Times Cited: 5
Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets
Elena Conte, Brigida Boccanegra, Giorgia Dinoi, et al.
Biomolecules (2024) Vol. 14, Iss. 9, pp. 1190-1190
Open Access | Times Cited: 4
Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD)
Felician Stancioiu, Raluca Bogdan, Radu Dumitrescu
Life (2023) Vol. 13, Iss. 8, pp. 1736-1736
Open Access | Times Cited: 10
Nested case-control study of intervention in early infancy to prevent tuberous sclerosis complex associated renal angiomyolipoma
Shuo Dun, Lin Wan, Yang‐Yang Wang, et al.
Kidney International Reports (2025)
Open Access
Neurologic orphan diseases: Emerging innovations and role for genetic treatments
Ivelina Kioutchoukova, Devon Foster, Rajvi Thakkar, et al.
World Journal of Experimental Medicine (2023) Vol. 13, Iss. 4, pp. 59-74
Open Access | Times Cited: 6
Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD)
Felician Stancioiu, Raluca Bogdan, Radu Dumitrescu
(2023)
Open Access | Times Cited: 5
An update on the novel methods for the discovery of antiseizure and antiepileptogenic medications: where are we in 2024?
Alan Talevi, Carolina L. Bellera
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 8, pp. 975-990
Closed Access | Times Cited: 1
Early therapy with sirolimus reduces size of a large solid renal mass but not seizure activity in an infant with tuberous sclerosis
Salar Bani Hani, Maddy Artunduaga, Kathleen Ludwig, et al.
Journal of Nephrology (2023) Vol. 37, Iss. 1, pp. 203-205
Closed Access | Times Cited: 1
Sirolimus

Reactions Weekly (2023) Vol. 1965, Iss. 1, pp. 439-439
Closed Access
Page 1

Scroll to top